Localization of identified advanced glycation end-product structures, Nε=(carboxymethyl)lysine and pentosidine, in age-related inclusions in human brains

The recent identification of age-related accumulation of advanced glycation end-products (AGE) of the Maillard reaction In neurons and vessels of the human brain suggests the involvement of AGE in the aging process. A variety of inclusions such as lipofuscin granules, corpora amylacea, Hirano bodies, granulovacuolar degenerations and ubiquitin-positive granular structures are found in the aged human brain. These age-related Inclusions contain insoluble and non-degradable proteins. Advanced glycation end-product-modified proteins are also known to be insoluble and protease resistant. The similarlty between proteins in such inclusions and AGE-modified proteins suggests the presence of AGE in inclusions. To investigate this possiblllty, the presence of two known AGE structures, N- (carboxymethyl)lysine (CML) and pentosidine, was exarnined in age-related inclusions. immunohistochemical examination of the medial temporal area of brain tissues obtained at autopsy from seven nondemented elderly individuals demonstrated positive reactions in lipofuscin granules and corpora amylacea but not in other inclusions for anti-CML and anti-pentosldine antibodies. As CML and pentosidine are glycoxidation products among AGE, the results suggest that glycation andor Oxidation may be involved In the formation of lipofuscin granules and corpora amylacea.     

Pelvic plexus contributes ganglion cells to the hindgut enteric nervous system.

The hindgut enteric nervous system (ENS) contains cells originating from vagal and sacral neural crest. In avians, the sacral crest gives rise to the nerve of Remak (NoR) and pelvic plexus. Whereas the NoR has been suggested to serve as the source of sacral crest-derived cells to the gut, the contribution of the pelvic ganglia is unknown. The purpose of this study was to test the hypothesis that the pelvic ganglia contribute ganglion cells to the hindgut ENS. We observed that the quail pelvic plexus develops from neural crest-derived cells that aggregate around the cloaca at embryonic day 5. Using chick-quail tissue recombinations, we found that hindgut grafts did not contain enteric ganglia unless the pelvic plexus was included. Neurofibers extended from the NoR into the intestine, but no ganglion cell contribution from the NoR was identified. These results demonstrate that the pelvic plexus, and not the NoR, serves as the staging area for sacral crest-derived cells to enter the avian hindgut, confirming the evolutionary conservation of this important embryologic process.     

益智宁神颗粒对SHR大鼠前额叶-纹状体多巴胺含量、GDNF mRNA及其蛋白表达的影响

[目的]研究益智宁神颗粒对幼龄自发性高血压(SHR)大鼠前额叶-纹状体多巴胺含量、胶质细胞源性神经营养因子(GDNF)mRNA及其蛋白表达的影响。[方法]以32只幼年SHR大鼠为研究对象,采用随机区组法分为模型对照组、益智宁神组、盐酸哌甲酯组、托莫西汀组,另设8只京都(WKY)大鼠为正常对照组。按各组设计剂量连续给药4周后,取前额叶、纹状体,采用高效液相法检测多巴胺(DA)含量、逆转录-聚合酶链反应(RT-PCR)法检测GDNF mRNA表达、蛋白免疫印迹(Western blot)法检测GDNF蛋白表达。[结果]1)SHR各组大鼠前额叶、纹状体DA的含量均有低于WKY组的趋势,其中,益智宁神组大鼠前额叶DA含量明显高于模型对照组(P0.05);益智宁神组大鼠纹状体DA含量低于正常对照组、盐酸托莫西汀组(P0.05)。2)SHR各组前额叶、纹状体GDNF mRNA表达依次为盐酸托莫西汀组盐酸哌甲酯组益智宁神组模型对照组(P0.05)。3)SHR大鼠各组间前额叶、纹状体GDNF蛋白表达均高于WKY组;其中,益智宁神组前额叶GDNF蛋白表达与其余SHR大鼠各组无统计学差异(P0.05),其纹状体GDNF蛋白表达低于盐酸哌甲酯组(P0.05)。[结论]益智宁神颗粒能够提高SHR特定脑区DA含量、GDNF mRNA及其蛋白表达,对促进幼龄SHR大鼠特定脑区DA能神经网络成熟度具有一定的作用。     

虎地肠溶胶囊对宫颈癌放射治疗致急性肠损伤的防护作用

目的 探讨虎地肠溶胶囊对宫颈癌患者放射性肠损伤的治疗效果。方法 将54例宫颈癌患者随机分成对照组和观察组,每组27例,对照组予以同步放射治疗和化学治疗,观察组在对照组基础上加用虎地肠溶胶囊;观察两组放射性损伤发生的时间、严重程度;放射治疗前后采用磁共振小肠造影（magnetic resonance enterography, MRE）检查肠损伤程度;采用欧洲癌症研究和治疗组织的30条目生活质量问卷（The European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Count 30, EORTC QLQ C30）评估两组患者放射性治疗前后生活质量。结果 观察组放射性肠损伤出现时间较对照组显著延迟（P＜0.05）;两组放射性肠损伤分级比较,差异无统计学意义(P＞0.05);MRE检查结果显示,两组放射治疗后小肠黏膜均明显增厚（P＜0.05）,观察组肠黏膜厚度增加程度显著小于对照组（P＜0.05）。EORTC QLQ C30显示虎地肠溶胶囊能够明显改善放射治疗致急性肠损伤的宫颈癌患者的生活质量。结论 虎地肠溶胶囊可有效延缓宫颈癌患者放射治疗后放射性肠损伤的发生,改善放射治疗后肠壁的水肿状态,提高患者生活质量。     

Add-on effect of Qinbei Qingfei Yiqi granules for ventilator-associated pneumonia in intensive care units: a randomized controlled trial

Objective

To evaluate the add-on effect of Qinbei Qingfei Yiqi (QBQFYQ) granules for ventilator-associated pneumonia (VAP) in non-infectious critically ill patients.

Evaluation of a granulated formula for the nerve root type and vertebral artery type of cervical spondylosis: a multicenter,single-blind,randomized, controlled,phase III clinical trial

Objective

To evaluate the effectiveness and safety of cervical spondylosis formula granules in reducing the symptoms of patients with the nerve root type and the vertebral artery type of cervical spondylosis.

疏肝利胆颗粒对胆管结石术后胆汁成分的影响

目的 :研究疏肝利胆颗粒对胆总管结石患者术后胆汁成分的影响。方法 :选取72例因胆总管结石行胆总管切开取石、T管引流手术患者,随机分为对照组和观察组各36例。对照组给予常规补液、抗感染等处理。观察组在此基础上,术后第2天给予胆汁回输,疏肝利胆颗粒每日1剂口服。总疗程28 d。每日记录胆汁引流量,分别于术中及服中药后7 d、14 d、28 d留取新鲜胆汁,检测胆汁总胆红素(TBIL)、非结合胆红素(UCB)、胆汁酸(TBA)、胆固醇(CHO)、磷脂(PL)、钙离子(Ca~(2+))浓度。结果 :观察组患者术后胆汁引流量明显高于对照组,差异有统计学意义(P<0.05)。观察组患者术后胆汁TBIL、UCB、CHO、Ca~(2+)下降较对照组明显,差异有统计学意义(P<0.05),胆汁TBA、PL升高较对照组明显,差异有统计学意义(P<0.05)。结论:疏肝利胆颗粒可以明显增加胆汁排出量,增加胆汁中总胆红素的排出,提高胆汁酸和磷脂的浓度,使胆汁趋向正常,从而降低胆汁成石性,对防治术后结石复发有一定作用。     

猴头菌提取物颗粒治疗小儿感染后脾虚综合征106例分析

目的:探讨猴头菌提取物颗粒治疗小儿感染后脾虚综合征的临床疗效.方法:选取2016年1月至2016年12月106例小儿感染后脾虚综合征患者,根据随机数字法,将其分为对照组(双歧杆菌乳杆菌三联活菌片,48例)和观察组(对照组治疗基础上,给予猴头菌提取物颗粒,58例),比较两组治疗的总体疗效、治疗前后体液免疫及细胞免疫指标变化情况.结果:与对照组相比,观察组治疗的总有效率明显增高(96.6%vs70.8%,P<0.05),差异有统计学意义;与对照组相比,观察组明显改善患儿体液免疫功能,治疗后IgG、IgA水平均明显增高(P<0.05),差异有统计学意义;与对照组相比,观察组有效改善患儿细胞免疫功能,治疗后CD3、CD4、CD4/CD8水平均明显增高(P<0.05),差异有统计学意义.结论:猴头菌提取物颗粒能够明显改善感染后脾虚综合征患儿免疫功能,提高治疗的临床疗效.     

小儿厌食颗粒联合布拉氏酵母菌治疗小儿厌食症的临床疗效及对血清细胞因子的影响

目的：探讨小儿厌食颗粒联合布拉氏酵母菌治疗小儿厌食症的临床疗效及对血清细胞因子的影响。方法：选取金华市人民医院2015年10月至2017年10月收治的小儿厌食症患儿240例,随机分为3组,各80例,联合组服用小儿厌食颗粒,l~3岁,1包/次;4~6岁,2包/次,每天3次口服,联合布拉氏酵母菌0.5 g/次,2次/d,饭前15~30 min口服。布拉氏酵母菌组单独服用布拉氏酵母菌,方法同联合组。小儿厌食颗粒组单独服用小儿厌食颗粒,方法同联合组。8周为1个疗程。同时检测3组血清细胞因子血清瘦素（Leptin）,P物质（SP）和促人生长激素腺释放肽（Ghrelin）。观察两组临床疗效、体质量与身高改善情况和血清细胞因子水平变化。结果：联合组总好转率91.25%,显著高于布拉氏酵母菌组的71.25%与小儿厌食颗粒组的73.75%（P<0.01）;联合组总有效率95.00%,显著高于布拉氏酵母菌组的71.25%与小儿厌食颗粒组的70.00%（P<0.01）;治疗8周后,联合组患儿Leptin水平较布拉氏酵母菌、小儿厌食颗粒组降低更显著（P<0.01）。联合组患儿SP及Ghrelin水平较布拉氏酵母菌,小儿厌食颗粒组上升更显著（P<0.01）,但上述细胞因子布拉氏酵母菌组和小儿厌食颗粒组比较差异无统计学意义。对3组治疗有效者进行6个月随访（剔除失访者）,治疗前3组体质量与身高比较差异无统计学意义,治疗后3组体质量与身高均较本组治疗前增加（P<0.05,P<0.01）,联合组显著优于布拉氏酵母菌和小儿厌食颗粒组（P<0.01）,布拉氏酵母菌、小儿厌食颗粒组比较差异无统计学意义。结论：小儿厌食颗粒联合布拉氏酵母菌治疗小儿厌食症能提高临床总有效率,调整血清细胞因子水平,增加身高与体质量。     

Temperature-sensitive heparin-modified poloxamer hydrogel with affinity to KGF facilitate the morphologic and functional recovery of the injured rat uterus

Endometrial injury usually results in intrauterine adhesion (IUA), which is an important cause of infertility and recurrent miscarriage in reproductive women. There is still lack of an effective therapeutic strategy to prevent occurrence of IUA. Keratinocyte growth factor (KGF) is a potent repair factor for epithelial tissues. Here, a temperature-sensitive heparin-modified poloxamer (HP) hydrogel with affinity to KGF (KGF-HP) was used as a support matrix to prevent IUA and deliver KGF. The rheology of KGF-HP hydrogel was carefully characterized. The cold KGF-HP solution was rapidly transited to hydrogel with suitable storage modulus (G′) and loss modulus (G″) for the applications of uterus cavity at temperature of 33?°C. In vitro release demonstrated that KGF was released from HP hydrogels in sustained release manner for a long time. In vivo bioluminescence imaging showed that KGF-HP hydrogel was able to prolong the retention of the encapsulated KGF in injured uterus of rat model. Moreover, the morphology and function of the injured uterus were significantly recovered after administration of KGF-HP hydrogel, which were evaluated by two-dimensional ultrasound imaging and receptive fertility. Not only proliferation of endometrial glandular epithelial cells and luminal epithelial cells but also angiogenesis of injured uterus were observed by Ki67 and CD31 staining after 7?d of treatment with KGF-HP hydrogel. Finally, a close relatively relationship between autophagy and proliferation of endometrial epithelial cells (EEC) and angiogenesis was firstly confirmed by detecting expression of LC3-II and P62 after KGF treatment. Overall, KGF-HP may be used as a promising candidate for IUA treatment.